Abbisko Cayman (STU:8ZD) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Abbisko Cayman's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.36 Mil. Abbisko Cayman's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.23 Mil. Abbisko Cayman's annualized Revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.

Abbisko Cayman Debt-to-Revenue Historical Data

The historical data trend for Abbisko Cayman's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Debt-to-Revenue Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

2.37

N/A

1.87

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial			1.19	N/A	N/A	1.07	N/A

Competitive Comparison of Abbisko Cayman's Debt-to-Revenue

For the Biotechnology subindustry, Abbisko Cayman's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Debt-to-Revenue falls into.

Abbisko Cayman Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Abbisko Cayman's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.363	+	3.225)	/	2.448
	=	1.87

Abbisko Cayman's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.363	+	3.225)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Abbisko Cayman Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (STU:8ZD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

02256:Hong Kong

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman (STU:8ZD) Headlines

No Headlines